Henlius Targets 20+ Global Launches by 2030 Under 'Globalisation 2.0' Strategy
Event summary
- Henlius CEO Jason Zhu unveiled 'Globalisation 2.0' strategy at JPM 2026, targeting over 20 product launches globally by 2030.
- Company expects more than 15 products in U.S. and European markets under this expansion plan.
- Stable cash flows from biosimilar portfolio to fund innovation in ADCs, multi-Abs, and TCEs through 2026.
- Key innovation assets for 2026 include serplulimab (Hetronifly®), HLX22, HLX43, and HLX07.
The big picture
Henlius is doubling down on international expansion amid a competitive biotech landscape where scale and regulatory approvals determine market leadership. The company's strategy aligns with broader industry trends of diversifying revenue streams through biosimilars while investing in next-generation therapies to drive long-term growth.
What we're watching
- Execution Risk
- Whether Henlius can sustain its rapid international growth while maintaining operational efficiency.
- Regulatory Momentum
- The pace at which Henlius secures additional approvals in key markets like the U.S. and Europe.
- Innovation Pipeline
- How successfully Henlius advances its differentiated molecules, including ADCs and multi-Abs, into global markets.
Related topics